Investors Sell Bristol-Myers Squibb (BMY) on Strength (BMY)

Investors sold shares of Bristol-Myers Squibb Co (NYSE:BMY) on strength during trading hours on Friday. $177.54 million flowed into the stock on the tick-up and $580.67 million flowed out of the stock on the tick-down, for a money net flow of $403.13 million out of the stock. Of all companies tracked, Bristol-Myers Squibb had the 12th highest net out-flow for the day. Bristol-Myers Squibb traded up $0.07 for the day and closed at $49.96

A number of equities analysts have recently weighed in on the stock. ValuEngine raised shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, December 7th. Bank of America lowered their price target on shares of Bristol-Myers Squibb from $53.00 to $51.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 19th. Morgan Stanley set a $54.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Thursday, December 20th. Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Thursday, January 3rd. Finally, Credit Suisse Group reaffirmed a “hold” rating and issued a $59.00 price objective on shares of Bristol-Myers Squibb in a research report on Friday, February 15th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the stock. Bristol-Myers Squibb has a consensus rating of “Hold” and an average price target of $59.40.

The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.50 and a current ratio of 1.61. The stock has a market capitalization of $80.88 billion, a price-to-earnings ratio of 12.55, a P/E/G ratio of 2.22 and a beta of 0.81.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, January 24th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.09. Bristol-Myers Squibb had a net margin of 21.95% and a return on equity of 48.99%. The business had revenue of $5.97 billion during the quarter, compared to the consensus estimate of $5.95 billion. During the same quarter last year, the company earned $0.68 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Research analysts anticipate that Bristol-Myers Squibb Co will post 4.15 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 3.28%. The ex-dividend date is Thursday, April 4th. Bristol-Myers Squibb’s payout ratio is currently 41.21%.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Capital Investment Counsel Inc lifted its stake in Bristol-Myers Squibb by 3.4% in the fourth quarter. Capital Investment Counsel Inc now owns 6,156 shares of the biopharmaceutical company’s stock valued at $320,000 after buying an additional 200 shares during the last quarter. Seizert Capital Partners LLC lifted its stake in Bristol-Myers Squibb by 3.8% in the fourth quarter. Seizert Capital Partners LLC now owns 6,069 shares of the biopharmaceutical company’s stock valued at $315,000 after buying an additional 224 shares during the last quarter. Modera Wealth Management LLC lifted its stake in Bristol-Myers Squibb by 4.3% in the fourth quarter. Modera Wealth Management LLC now owns 5,567 shares of the biopharmaceutical company’s stock valued at $289,000 after buying an additional 229 shares during the last quarter. Cetera Investment Advisers lifted its stake in Bristol-Myers Squibb by 0.8% in the fourth quarter. Cetera Investment Advisers now owns 29,595 shares of the biopharmaceutical company’s stock valued at $1,537,000 after buying an additional 230 shares during the last quarter. Finally, Private Wealth Advisors Inc. lifted its stake in Bristol-Myers Squibb by 5.0% in the fourth quarter. Private Wealth Advisors Inc. now owns 4,873 shares of the biopharmaceutical company’s stock valued at $253,000 after buying an additional 232 shares during the last quarter. Hedge funds and other institutional investors own 73.35% of the company’s stock.

WARNING: “Investors Sell Bristol-Myers Squibb (BMY) on Strength (BMY)” was published by WKRB News and is the sole property of of WKRB News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at https://www.wkrb13.com/2019/03/16/investors-sell-bristol-myers-squibb-bmy-on-strength-bmy.html.

Bristol-Myers Squibb Company Profile (NYSE:BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

Read More: Market Capitalization – What it Means for Investors

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.